Ben Leach


Immediate Impact Anticipated From Neoadjuvant Pertuzumab

November 27th 2013

The new indication for pertuzumab (Perjeta) as part of a three-drug neoadjuvant regimen for patients with HER2-positive metastatic breast cancer marks the first time the FDA has authorized a therapy based on pathologic complete response.

Misdiagnoses and Sequencing in Melanoma

November 5th 2013

After decades with few available therapies, a flurry of FDA drug approvals has provided oncologists with a variety of options for treating patients with advanced melanoma.

Perioperative Breast MRI Does Not Lower Recurrence Risk for Early-Stage Patients

October 24th 2013

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence

A Leader in Both Research and Practice

October 15th 2013

Few of ASCO's past presidents were faced with the multitude of challenges that arose during the presidency of Sandra M. Swain, MD, who is medical director of the Washington Cancer Institute at Medstar Washington Hospital Center and a professor of Medicine at Georgetown University, and is currently ASCO's immediate past president.

Promising TH-302 Results Accelerate Sarcoma Study

September 25th 2013

The list of agents currently available to treat soft-tissue sarcoma is rather short, with no drugs being approved on the basis of an improvement in overall survival in approximately 20 years.

New Data May Dispel Safety Concerns With 5-ARI Use in Prostate Cancer Prevention

September 19th 2013

The Prostate Cancer Prevention Trial, conducted from January 1997 to February 2003, demonstrated that the 5α-reductase inhibitor (5-ARI) finasteride reduced the risk of developing prostate cancer in men being regularly screened for the disease

PAM50 Demonstrates Added Clinical Value in Predicting Recurrence Risk

September 19th 2013

The PAM50 test, designed to determine a risk of recurrence score for patients with breast cancer, adds significant prognostic information to clinical decision making and might be superior to other risk assays.

Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL

September 16th 2013

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12th 2013

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

FDA Panel Set to Vote on Milestone Neoadjuvant Pertuzumab Combo

September 11th 2013

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.